世界胃肠病理生理学杂志(电子版)(英文版)最新文献_第4页

Upper gastrointestinal bleeding risk scores: Who, when and why? 上消化道出血风险评分:何人、何时、为何?

世界胃肠病理生理学杂志(电子版)(英文版) Pub Date : 2016-02-15 DOI: 10.4291/wjgp.v7.i1.86

S. Monteiro, T. Gonçalves, J. Magalhães, J. Cotter

{"title":"Upper gastrointestinal bleeding risk scores: Who, when and why?","authors":"S. Monteiro, T. Gonçalves, J. Magalhães, J. Cotter","doi":"10.4291/wjgp.v7.i1.86","DOIUrl":"https://doi.org/10.4291/wjgp.v7.i1.86","url":null,"abstract":"Upper gastrointestinal bleeding (UGIB) remains a significant cause of hospital admission. In order to stratify patients according to the risk of the complications, such as rebleeding or death, and to predict the need of clinical intervention, several risk scores have been proposed and their use consistently recommended by international guidelines. The use of risk scoring systems in early assessment of patients suffering from UGIB may be useful to distinguish high-risks patients, who may need clinical intervention and hospitalization, from low risk patients with a lower chance of developing complications, in which management as outpatients can be considered. Although several scores have been published and validated for predicting different outcomes, the most frequently cited ones are the Rockall score and the Glasgow Blatchford score (GBS). While Rockall score, which incorporates clinical and endoscopic variables, has been validated to predict mortality, the GBS, which is based on clinical and laboratorial parameters, has been studied to predict the need of clinical intervention. Despite the advantages previously reported, their use in clinical decisions is still limited. This review describes the different risk scores used in the UGIB setting, highlights the most important research, explains why and when their use may be helpful, reflects on the problems that remain unresolved and guides future research with practical impact.","PeriodicalId":68755,"journal":{"name":"世界胃肠病理生理学杂志(电子版)(英文版)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4291/wjgp.v7.i1.86","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71059770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 60

Current application of proteomics in biomarker discovery for inflammatory bowel disease. 蛋白质组学在炎性肠病生物标志物发现中的应用现状

世界胃肠病理生理学杂志(电子版)(英文版) Pub Date : 2016-02-15 DOI: 10.4291/wjgp.v7.i1.27

Patrick Py Chan, V. Wasinger, R. Leong

{"title":"Current application of proteomics in biomarker discovery for inflammatory bowel disease.","authors":"Patrick Py Chan, V. Wasinger, R. Leong","doi":"10.4291/wjgp.v7.i1.27","DOIUrl":"https://doi.org/10.4291/wjgp.v7.i1.27","url":null,"abstract":"Recently, the field of proteomics has rapidly expanded in its application towards clinical research with objectives ranging from elucidating disease pathogenesis to discovering clinical biomarkers. As proteins govern and/or reflect underlying cellular processes, the study of proteomics provides an attractive avenue for research as it allows for the rapid identification of protein profiles in a biological sample. Inflammatory bowel disease (IBD) encompasses several heterogeneous and chronic conditions of the gastrointestinal tract. Proteomic technology provides a powerful means of addressing major challenges in IBD today, especially for identifying biomarkers to improve its diagnosis and management. This review will examine the current state of IBD proteomics research and its use in biomarker research. Furthermore, we also discuss the challenges of translating proteomic research into clinically relevant tools. The potential application of this growing field is enormous and is likely to provide significant insights towards improving our future understanding and management of IBD.","PeriodicalId":68755,"journal":{"name":"世界胃肠病理生理学杂志(电子版)(英文版)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4291/wjgp.v7.i1.27","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71060131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 35

Magnetic resonance imaging biomarkers of gastrointestinal motor function and fluid distribution. 胃肠道运动功能和体液分布的磁共振成像生物标志物。

世界胃肠病理生理学杂志(电子版)(英文版) Pub Date : 2015-11-15 DOI: 10.4291/wjgp.v6.i4.140

Asseel Khalaf, C. Hoad, R. Spiller, P. Gowland, G. Moran, L. Marciani

引用次数: 12

Role of cancer stem cells in age-related rise in colorectal cancer. 癌症干细胞在结直肠癌年龄相关性上升中的作用。

世界胃肠病理生理学杂志(电子版)(英文版) Pub Date : 2015-11-15 DOI: 10.4291/wjgp.v6.i4.86

P. Nangia-Makker, Yingjie Yu, A. Majumdar

{"title":"Role of cancer stem cells in age-related rise in colorectal cancer.","authors":"P. Nangia-Makker, Yingjie Yu, A. Majumdar","doi":"10.4291/wjgp.v6.i4.86","DOIUrl":"https://doi.org/10.4291/wjgp.v6.i4.86","url":null,"abstract":"Colorectal cancer (CRC) that comprises about 50% of estimated gastrointestinal cancers remains a high mortality malignancy. It is estimated that CRC will result in 9% of all cancer related deaths. CRC is the third leading malignancy affecting both males and females equally; with 9% of the estimated new cancer cases and 9% cancer related deaths. Sporadic CRC, whose incidence increases markedly with advancing age, occurs in 80%-85% patients diagnosed with CRC. Little is known about the precise biochemical mechanisms responsible for the rise in CRC with aging. However, many probable reasons for this increase have been suggested; among others they include altered carcinogen metabolism and the cumulative effects of long-term exposure to cancer-causing agents. Herein, we propose a role for self-renewing, cancer stem cells (CSCs) in regulating these cellular events. In this editorial, we have briefly described the recent work on the evolution of CSCs in gastro-intestinal track especially in the colon, and how they are involved in the age-related rise in CRC. Focus of this editorial is to provide a description of (1) CSC; (2) epigenetic and genetic mechanisms giving rise to CSCs; (3) markers of CSC; (4) characteristics; and (5) age-related increase in CSC in the colonic crypt.","PeriodicalId":68755,"journal":{"name":"世界胃肠病理生理学杂志(电子版)(英文版)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2015-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71058977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Lymphoproliferative disorders in inflammatory bowel disease patients on immunosuppression: Lessons from other inflammatory disorders. 炎症性肠病患者淋巴增生性疾病对免疫抑制的影响:来自其他炎症性疾病的经验教训。

世界胃肠病理生理学杂志(电子版)(英文版) Pub Date : 2015-11-15 DOI: 10.4291/wjgp.v6.i4.181

G. Lam, B. Halloran, A. Peters, R. Fedorak

{"title":"Lymphoproliferative disorders in inflammatory bowel disease patients on immunosuppression: Lessons from other inflammatory disorders.","authors":"G. Lam, B. Halloran, A. Peters, R. Fedorak","doi":"10.4291/wjgp.v6.i4.181","DOIUrl":"https://doi.org/10.4291/wjgp.v6.i4.181","url":null,"abstract":"Immunosuppressive agents, such as thiopurines, methotrexate, and biologics, have revolutionized the treatment of inflammatory bowel disease (IBD). However, a number of case reports, case control studies and retrospective studies over the last decade have identified a concerning link between immunosuppression and lymphoproliferative disorders (LPDs), the oncological phenomenon whereby lymphocytes divide uncontrollably. These LPDs have been associated with Epstein-Barr virus (EBV) infection in which the virus provides the impetus for malignant transformation while immunosuppression hampers the immune system's ability to detect and clear these malignant cells. As such, the use of immunosuppressive agents may come at the cost of increased risk of developing LPD. While little is known about the LPD risk in IBD, more is known about immunosuppression in the post-transplantation setting and the development of EBV associated post-transplantation lymphoproliferative disorders (PTLD). In review of the PTLD literature, evidence is available to demonstrate that certain immune suppressants such as cyclosporine and T-lymphocyte modulators in particular are associated with an increased risk of PTLD development. As well, high doses of immunosuppressive agents and multiple immunosuppressive agent use are also linked to increased PTLD development. Here, we discuss these findings in context of IBD and what future studies can be taken to understand and reduce the risk of EBV-associated LPD development from immunosuppression use in IBD.","PeriodicalId":68755,"journal":{"name":"世界胃肠病理生理学杂志(电子版)(英文版)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2015-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71059085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 19

Role of anti-stromal polypharmacy in increasing survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. 抗间质多药在胰管腺癌胰十二指肠切除术后提高生存率中的作用。

世界胃肠病理生理学杂志(电子版)(英文版) Pub Date : 2015-11-15 DOI: 10.4291/wjgp.v6.i4.235

S. Tingle, J. Moir, S. White

{"title":"Role of anti-stromal polypharmacy in increasing survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.","authors":"S. Tingle, J. Moir, S. White","doi":"10.4291/wjgp.v6.i4.235","DOIUrl":"https://doi.org/10.4291/wjgp.v6.i4.235","url":null,"abstract":"AIM\u0000To investigate the survival impact of common pharmaceuticals, which target stromal interactions, following a pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.\u0000\u0000\u0000METHODS\u0000Data was collected retrospectively for 164 patients who underwent a pancreaticoduodenectomy for pancreatic ductal adenocarcinoma (PDAC). Survival analysis was performed on patients receiving the following medications: angiotensin-converting enzyme inhibitors (ACEI)/angiotensin II receptor blockers (ARB), calcium channel blockers (CCB), aspirin, and statins. Statistical analysis included Kaplan-meier survival estimates and cox multivariate regression; the latter of which allowed for any differences in a range of prognostic indicators between groups. Medications showing a significant survival benefit were investigated in combination with other medications to evaluate synergistic effects.\u0000\u0000\u0000RESULTS\u0000No survival benefit was observed with respect to ACEI/ARB (n = 41), aspirin or statins on individual drug analysis (n = 39). However, the entire CCB group (n = 26) showed a significant survival benefit on multivariate cox regression; hazard ratio (HR) of 0.475 (CI = 0.250-0.902, P = 0.023). Further analysis revealed that this was influenced by a group of patients who were taking aspirin in combination with CCB; median survival was significantly higher in the CCB + aspirin group (n = 15) compared with the group taking neither drug (n = 98); 1414 d vs 601 d (P = 0.029, log-rank test). Multivariate cox regression revealed neither aspirin nor CCB had a statistically significant impact on survival when given alone, however in combination the survival benefit was significant; HR = 0.332 (CI = 0.126-0.870, P = 0.025). None of the other medications showed a survival benefit in any combination.\u0000\u0000\u0000CONCLUSION\u0000Aspirin + CCB in combination appears to increase survival in patients with PDAC, highlighting the potential clinical use of combination therapy to target stromal interactions in pancreatic cancer.","PeriodicalId":68755,"journal":{"name":"世界胃肠病理生理学杂志(电子版)(英文版)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2015-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71058921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Energetic etiologies of acute pancreatitis: A report of five cases. 急性胰腺炎的能量性病因:附5例报告。

世界胃肠病理生理学杂志(电子版)(英文版) Pub Date : 2015-11-15 DOI: 10.4291/wjgp.v6.i4.243

A. Shmelev, Alain Abdo, Sarina Sachdev, U. Shah, G. Kowdley, S. Cunningham

引用次数: 9

Alcoholic hepatitis: The pivotal role of Kupffer cells. 酒精性肝炎:库普弗细胞的关键作用。

世界胃肠病理生理学杂志(电子版)(英文版) Pub Date : 2015-11-15 DOI: 10.4291/wjgp.v6.i4.90

Duminda Suraweera, Ashley N Weeratunga, Robin Hu, S. Pandol, Richard Hu

引用次数: 18

Starring role of toll-like receptor-4 activation in the gut-liver axis. toll样受体-4激活在肠-肝轴中的主要作用。

世界胃肠病理生理学杂志(电子版)(英文版) Pub Date : 2015-11-15 DOI: 10.4291/wjgp.v6.i4.99

S. Carotti, M. Guarino, U. Vespasiani‐Gentilucci, S. Morini

引用次数: 40

Faecal calprotectin: Management in inflammatory bowel disease. 粪钙保护素:炎症性肠病的治疗。

世界胃肠病理生理学杂志(电子版)(英文版) Pub Date : 2015-11-15 DOI: 10.4291/wjgp.v6.i4.203

J. Benítez, V. García‐Sánchez

{"title":"Faecal calprotectin: Management in inflammatory bowel disease.","authors":"J. Benítez, V. García‐Sánchez","doi":"10.4291/wjgp.v6.i4.203","DOIUrl":"https://doi.org/10.4291/wjgp.v6.i4.203","url":null,"abstract":"Inflammatory bowel disease (IBD) is a chronic and relapsing disorder which leads to an inflammation of the gastrointestinal tract. A tailored therapy to achieve mucosal healing with the less adverse events has become a key issue in the management of IBD. In the past, the clinical remission was the most important factor to consider for adapting diagnostic procedures and therapeutic strategies. However, there is no a good correlation between symptoms and intestinal lesions, so currently the goals of treatment are to achieve not only the control of symptoms, but deep remission, which is related with a favourable prognosis. Thus, the determination of biological markers or biomarkers of intestinal inflammation play a crucial role. Many biomarkers have been extensively evaluated in IBD showing significant correlation with endoscopic lesions, risk of recurrence and response to treatment. One of the most important markers is faecal calprotectin (FC). Despite calprotectin limitations, this biomarker represents a reliable and noninvasive alternative to reduce the need for endoscopic procedures. FC has demonstrated its performance for regular monitoring of IBD patients, not only to the diagnosis for discriminating IBD from non-IBD diagnosis, but for assessing disease activity, relapse prediction and response to therapy. Although, FC provides better results than other biomarkers such as C-reactive protein and erythrocyte sedimentation rate, these surrogate markers of intestinal inflammation should not be used isolation but in combination with other clinical, endoscopic, radiological or/and histological parameters enabling a comprehensive assessment of IBD patients.","PeriodicalId":68755,"journal":{"name":"世界胃肠病理生理学杂志(电子版)(英文版)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2015-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71058775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 24